Arthneeti
AE

Advanced Enzyme Technologies Ltd

Q1 FY26Pharmaceuticals & Biotechnology

Advanced Enzyme Technologies Ltd Q1 FY26 Results & Concall Highlights: Revenue, Margins & Order Book

Q1 FY26 earnings call: what management guided on revenue, margins and order book.

Price₹300
Market cap₹3.7K Cr
P/E24.0
Updated23 Aug 2026
Read5 min read

The short version

The company targets double-digit growth over the longer run but is cautious about predicting exact figures due to product mix and market cycles. The company targets sustained double-digit growth over the medium to long term rather than very high short-term spikes.

From Advanced Enzyme Technologies Ltd's Q1 FY26 earnings-call transcript · updated 23 Aug 2026.

Revenue & Sales Performance

  • The company targets double-digit growth over the longer run but is cautious about predicting exact figures due to product mix and market cycles.
  • Medium-term outlook expects maintaining or improving current momentum, with hopes to touch about 80% capacity utilization within 2 years before next capacity expansion.
  • Focus remains on segments like Human Nutrition (notably Pharma and Probiotics) and Animal Nutrition, with some new products and biocatalyst applications under development.
  • Regulatory changes favoring green chemistry and biocatalysts, especially in developed countries, could positively impact demand.
  • Sales growth in probiotics is part of blends with enzymes; difficult to segregate but seen as a growth area.
  • Current volume growth measurement is not emphasized, given wide product price range; volume growth impact uncertain.
  • Growth seen as patchy but overall optimistic; guidance for mid to high teens growth for FY '26 maintained despite tariff uncertainties.

Profitability & Margins

See what Advanced Enzyme Technologies Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • The company has been investing significantly in a new R&D facility at Nashik, with about INR48 crores already spent; this expense is currently under work in progress and not included in regular R&D expenditure.
  • The new R&D center is expected to be commissioned by the last quarter of this fiscal year.
  • Management is open to capacity expansions whenever capacity utilization approaches around 80%, which they hope to reach in about 2 years, indicating future capex in manufacturing capacity.
  • There is mention of ongoing product development and research across various segments, suggesting continuous investment in innovation.
  • Strategic expansions include broadening their product portfolio and entering new markets, but specifics on acquisitions are currently premature.
  • One subsidiary, JC Biotech, is investing in clean energy by collaborating with Raywatt Solar Power Systems to meet electricity needs sustainably and cost-effectively.

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

5x potential
1Accretion Pharmaceuticals Ltd
Rev 1Mar 2
2OneSource Speci.
Rev 1Mar 3
3
Rev 1Mar 3
4
Rev 1Mar 3
5
Rev 2Mar 1
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Advanced Enzyme Technologies Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

The transcript does not explicitly mention the current or expected order book or pending orders for Advanced Enzyme Technologies Limited. However, some relevant insights related to business outlook and sales pipeline are: - Growth is driven by ongoing projects from the last 1-2 years in both export and domestic markets beginning to materialize. - Management is optimistic about sustaining growth in key segments like Human Nutrition and Animal Nutrition. - The company is focused on expanding business in these areas while working on new sectors and products, including probiotics and biocatalysts. - R&D efforts and patent filings aim to convert into future sales, though exact timelines or order visibility are unclear. - Capacity utilization is around 60-65%, expected to reach 80% in about 2 years, prompting potential capacity expansion to meet demand. - Tariff impact on exports to the U.S. is estimated around INR50 crores for the year, influencing negotiations and pricing. There is no explicit detail on a quantified current order book or pending orders in the provided pages.

Advanced Enzyme Technologies Ltd — Quarterly revenue & net profit

Revenue Net profit
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026

Reported quarterly figures (₹ Cr). Latest: revenue ₹203 Cr, net profit ₹45 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Continue your research

What Advanced Enzyme's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

  • Sai Life (Q1 FY26)

    Sai Life Sciences reported a strong Q1 FY'26 with revenue up 77% YoY, driven mainly by CDMO (113% growth) and CRO (38% growth). Key concall takeaways from Sai…

  • Cipla (Q1 FY26)

    One Africa business grew 11% YoY, with continued focus on expansion. Key concall takeaways from Cipla's Q1 FY26 earnings call — and how it ranks against sector…

  • Anthem Bioscienc (Q1 FY26)

    Capacity utilization in custom synthesis is around 70%, with expansions ongoing, indicating potential for further revenue growth. Key concall takeaways from…

  • Senores Pharma. (Q1 FY26)

    . Key concall takeaways from Senores Pharmaceuticals Ltd's Q1 FY26 earnings call — and how it ranks against sector peers.

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharma.

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Frequently Asked Questions

What were Advanced Enzyme Technologies Ltd Q1 FY26 results?

The company targets double-digit growth over the longer run but is cautious about predicting exact figures due to product mix and market cycles. The company targets sustained double-digit growth over the medium to long term rather than very high short-term spikes.

What is Advanced Enzyme Technologies Ltd share price analysis?

Advanced Enzyme Technologies Ltd currently shows a neutral. The stock trades at a P/E of 24.0 with a market cap of ₹3,726 Cr. Investors should review the full earnings analysis for detailed insights.

Is Advanced Enzyme Technologies Ltd planning capital expenditure?

The company has been investing significantly in a new R&D facility at Nashik, with about INR48 crores already spent; this expense is currently under work in progress and not included in regular R&D expenditure.

Keep Advanced Enzyme Technologies Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.